Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) is projected to release its earnings data before the market opens on Tuesday, February 4th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.42) per share and revenue of $19,050.00 billion for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
NASDAQ ARWR opened at $20.25 on Tuesday. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -4.03 and a beta of 0.97. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a twelve month low of $17.05 and a twelve month high of $36.72. The stock has a fifty day simple moving average of $20.76 and a 200 day simple moving average of $21.92.
In related news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares of the company's stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00. Following the completion of the sale, the chief executive officer now owns 3,764,252 shares of the company's stock, valued at approximately $71,709,000.60. The trade was a 0.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,432 shares of company stock valued at $2,957,986 over the last ninety days. 4.50% of the stock is owned by company insiders.
A number of equities analysts have recently issued reports on ARWR shares. Chardan Capital restated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Citigroup dropped their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 27th. Sanford C. Bernstein decreased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research report on Friday, November 29th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, January 23rd. Finally, Piper Sandler decreased their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $43.33.
Check Out Our Latest Stock Report on ARWR
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.